Protecting the Gut Microbiome

Synthetic Biologics is developing cutting-edge therapeutics to treat pathogen-specific diseases. 

Our two leading candidates are:
SYN-004 to prevent C. difficile infection and antibiotic-associated diarrhea
SYN-010 to treat irritable bowel syndrome with constipation (IBS-C)

View SYN-004 View SYN-010

About Synthetic Biologics

We are a clinical stage company developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. Founded in 2001, Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN".

Learn More


Our experienced management team has an extensive clinical and commercial track record.

Latest News

May 23, 2016 • 6:50am EDT

Synthetic Biologics Announces Detailed Data from Two SYN-010 Phase 2 Clinical Trials for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)

-- Phase 2 Clinical Trials Demonstrate Potential of SYN-010 to Reduce Abdominal Pain and Bloating, and Improve Stool Frequency and Quality of Life Scores without Severe Adverse Event

View all news

Investor Relations

Day Low/High
52 Week Low/High